SCHEMBL20435887

SCHEMBL20435887

O=c1c(Cl)c(Cl)cnn1Cc1nc(-c2ccc(Cl)cc2)no1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 6/20 0.62
▸ ALDH1A1 P00352 6/20 0.62
▸ HTT P42858 5/20 0.62
▸ MAPT P10636 4/20 0.62
▸ NPC1 O15118 3/20 0.62
▸ POLB P06746 3/20 0.62
▸ MEN1 O00255 2/20 0.62
▸ KMT2A Q03164 2/20 0.62
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ CYP1A2 P05177 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ MITF O75030 3/20 0.50
▸ NOTUM Q6P988 2/20 0.50
▸ NPSR1 Q6W5P4 2/20 0.50
▸ PKM P14618 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ BLM P54132 1/20 0.50
▸ GPR35 Q9HC97 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20435858 0.88 HPGD (0.55) RAB9AALDH1A1HTTMAPTNPC1
SCHEMBL20435863 0.82 RAB9A (0.59) RAB9AALDH1A1HTTMAPTNPC1
SCHEMBL25974095 0.80 TRPA1 (0.55) RAB9AALDH1A1HTTMAPTNPC1
SCHEMBL20435859 0.80 CYP1A2 (0.55) RAB9AALDH1A1HTTMAPTNPC1
SCHEMBL25124289 0.77 HTT (0.55) RAB9AALDH1A1HTTMAPTSMN1; SMN2
SCHEMBL20435890 0.77 AKR1B1 (0.55) RAB9AALDH1A1HTTMAPTNPC1
SCHEMBL17799191 0.77 HTT (1.00) RAB9AALDH1A1HTTMAPTNPC1
SCHEMBL19000706 0.75 HTT (0.77) RAB9AALDH1A1HTTMAPTNPC1
SCHEMBL20435870 0.74 HPGD (0.58) RAB9AALDH1A1HTTMAPTNPC1
SCHEMBL2094888 0.74 NOTUM (0.70) RAB9AALDH1A1HTTNPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity Zander Biologics, Inc (US) 2022-07-05 — — US disclosed
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans KCL THERAPEUTICS, INC. (US) 2022-05-10 — — US disclosed
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS Zander Therapeutics, Inc. (US) 2020-03-05 — — US disclosed
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals Zander Therapeutics, Inc. (US) 2019-11-12 — — US disclosed
WO-2019104199-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY REGEN BIOPHARMA INC. (US) 2019-05-31 — — WO disclosed
WO-2019104201-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN NON-HUMANS Zander Therapeutics, Inc. (US) 2019-05-31 — — WO disclosed
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals Zander Therapeutics, Inc. 2019-02-21 — — US disclosed
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC 2018-08-02 — — US disclosed
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans KCL THERAPEUTICS, INC 2018-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180214413-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Humans NR4A2, NR2C2, NR0B2 RAB9A 3645/4885ALDH1A1 2069/4885HTT 3739/4885
US-20200071307-A1 SMALL MOLECULE AGONISTS AND ANTAGONISTS OF NR2F6 ACTIVITY IN ANIMALS NR4A2, NR2C2, NR0B2 RAB9A 3469/4885ALDH1A1 1783/4885HTT 3928/4885
US-20190054118-A1 Small Molecule Agonists and Antagonists of NR2F6 Activity in Animals NR4A2, NR2C2, NR0B2 RAB9A 3469/4885ALDH1A1 1783/4885HTT 3928/4885
US-11324719-B2 Small molecule agonists and antagonists of NR2F6 activity in humans NR4A2, NR2C2, NR0B2 RAB9A 3645/4885ALDH1A1 2069/4885HTT 3739/4885
US-11377442-B2 Small molecule agonists and antagonists of NR2F6 activity NR4A2, NR2C2, NR2F2 RAB9A 3762/4885ALDH1A1 1909/4885HTT 4280/4885
US-10472351-B2 Small molecule agonists and antagonists of NR2F6 activity in animals NR4A2, NR2C2, NR0B2 RAB9A 3469/4885ALDH1A1 1783/4885HTT 3928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback